Updated July 2026 · 8 claims evaluated · Cited
Fact-check: common claims about women's hormonal health
The Dr. Jen Gunter-style category — five to seven high-traffic claims about HRT, GLP-1, compounded medication, and PCOS, evaluated against current evidence with verdict + sources + reasoning. We don't accept wellness-marketing framing OR dismiss skepticism. We read the studies and tell you what they say.
- Mostly falseGLP-1
“GLP-1 medications cause thyroid cancer in humans”
The FDA black-box warning is based on rodent studies. Human data has not shown elevated medullary thyroid cancer risk in clinical trials or post-market surveillance, though personal/family history of MEN-2 or medullary thyroid carcinoma remains a contraindication.
- FalseCompounded medication
“Compounded semaglutide is FDA-approved”
Compounded semaglutide is NOT FDA-approved as a drug. The active molecule (semaglutide) is FDA-approved in branded products (Wegovy, Ozempic) — the compounded formulation itself has no FDA approval. This is a common marketing misrepresentation.
- Mostly falseHRT
“Hormone replacement therapy causes breast cancer”
The 2002 WHI headline overstated risk for symptomatic women under 60. Current evidence (re-analyses, ELITE, KEEPS trials) shows the absolute breast cancer risk increase from combined HRT is small (~8 extra cases per 10,000 woman-years) and risk varies dramatically by timing, formulation, and individual factors. Estrogen-only HRT (no progestin) showed DECREASED breast cancer in WHI itself.
- FalsePCOS
“Only overweight women have PCOS”
Approximately 20% of women with PCOS are lean (BMI <25). "Lean PCOS" is well-documented and commonly misdiagnosed because BMI screening misses it. Insulin resistance can exist without obesity; androgen excess can present in any BMI range.
- FalseMenopause
“You're too young for perimenopause at 40”
Perimenopause typically begins in the early-to-mid 40s. Median age of final menstrual period in the US is 51, but the transition starts 5-10 years before that — meaning 40-45 is a very normal age for early symptoms. Premature ovarian insufficiency (POI) before age 40 is also real, requiring different workup.
- Mixed evidenceGLP-1
“Microdosing GLP-1 is effective and safe for perimenopausal weight management”
Microdosing GLP-1 (typically 0.1–0.25mg/week semaglutide or 1.25mg/week tirzepatide, below FDA-approved starting doses) lacks randomized trial data. Some clinicians prescribe it off-label citing improved tolerance; others warn it bypasses standard titration safety. Personal anecdotes outweigh published evidence — handle accordingly.
- UnprovenMenopause
“Cycle-syncing your fasting protocol improves perimenopausal weight”
Dr. Mindy Pelz's "Fast Like a Girl" framework — varying fasting windows by cycle phase — has zero randomized trial evidence in perimenopause specifically. Plausible mechanism (estrogen affects insulin sensitivity per cycle); zero proof it produces better outcomes than standard intermittent fasting or no fasting.
- Mostly falseMenopause
“Red light therapy devices treat vaginal atrophy as effectively as estrogen”
Devices like Joylux vFit have FDA "General Wellness" designation — not drug approval. Limited evidence shows modest improvement in some users. Comparison to local estrogen (well-evidenced gold standard) is inappropriate — they're different categories with different evidence bases.